The medication is considered relevant in contexts involving distressing symptoms for adult men. It is commonly used across conditions presenting with acute episodes associated with Benign Prostatic Hyperplasia (BPH) and chronic abacterial prostatitis. It is helpful in situations requiring additional symptomatic assistance, and may assist with easing the overall symptom burden linked to organ-specific functional stress.

It is relevant for easing symptom clusters that interfere with daily comfort, such as Lower Urinary Tract Symptoms (LUTS), including frequent urges, urgency, or the need to urinate during the night. It is also commonly used when short-term symptomatic assistance is needed to address symptoms related to physical discomfort in the pelvic or perineal region.

Quick Fact: Relief for Lower Urinary Tract Symptoms (LUTS)

The supportive relief contributes to improved comfort during periods of heightened symptoms, and may help patients cope more steadily when symptoms interfere with routine activities. The medication is commonly used to help with symptomatic manifestations of chronic prostatitis and conditions associated with fluctuating BPH symptoms.

Regulatory References

1. NIH MedlinePlus overview on PSA and Prostate Conditions

Official Regulatory Eligibility for Афала

The eligibility to use the medicine Афала is strictly determined by its official regulatory label, which outlines the specific populations for whom use is allowed, restricted, or prohibited.

Field	Official Regulatory Status
Populations for whom use is allowed	Intended only for the Adult Male Population as defined by its specific indications.
Populations for whom use is contraindicated	Individuals under 18 years of age; Female patients; Patients with Hypersensitivity to the drug's components (active or excipients).
Age-related eligibility rules	Use is contraindicated in all individuals under 18 years of age due to official lack of established efficacy and safety data in this younger cohort.
Condition-specific eligibility rules	Use is contraindicated in patients with specific metabolic disorders, including lactase deficiency, hereditary galactose intolerance, or glucose-galactose malabsorption.
Pregnancy and lactation eligibility status	Contraindicated (the medicine is not intended for use in the female population).

Connection to the overall eligibility profile

The eligibility profile is strictly defined by regulatory standards. The medicine is explicitly designated for adult male use and carries several absolute prohibitions. Use is officially contraindicated across the entire pediatric and adolescent population (under 18 years). Furthermore, official labeling prohibits the use of the medicine in any patient with a known allergy to its components or with specific excipient-related metabolic conditions. The official regulatory instruction provides no specific limitations concerning hepatic or renal impairment.

Interactions with other medicines and products

The official regulatory documents for the homeopathic medicinal product Афала define its interaction profile primarily by the absence of registered incompatibilities with other substances. Given its nature as an ultra-diluted preparation of Affinely Purified Antibodies to Prostate-specific Antigen, the official labeling provides specific information regarding the status of documented interactions.

Drug-Drug Interaction Status

The regulatory instructions explicitly state that no cases of incompatibility with other medicinal products have been registered to date. This regulatory status means the official prescribing information includes no formally contraindicated combinations or warnings regarding co-administration with any other specific medicines or product classes.

Furthermore, the documentation notes that drug interaction studies for the product have not been conducted. This results in the official label containing no specific information on the mechanistic basis of interactions, such as pharmacokinetic effects involving CYP enzymes or drug transporters, or pharmacodynamic effects that could alter the exposure of other medicines.

Interactions with Food, Alcohol, and Supplements

No specific interactions with alcohol, herbal products, or supplements are documented in the official labeling.

The only administration constraint related to intake is a timing rule: the tablet must be administered not during a meal ("вне приема пищи") to ensure proper use, which is a procedural constraint required for administration. The complete absence of documented interactions distinguishes the regulatory profile of this preparation.

Modulation of the Serine Protease, Prostate-specific Antigen (PSA)

The mechanism initiates at the molecular level with Affinely Purified Antibodies targeting the endogenous enzyme Prostate-specific Antigen (PSA). These Release-Active Antibodies function as allosteric modulators, inducing a conformational shift in the PSA molecule that serves to adjust the functional state of the enzyme within the prostate gland, rather than causing direct inhibition.

Mechanism for Influencing Local Inflammatory Pathways

The functional change in PSA activity initiates a downstream mechanistic cascade associated with the influence on localized inflammatory signaling and microvascular dysregulation within the prostate tissue. The resulting physiological effect is the dampening of pro-inflammatory signals and the reduction of prostate edema (swelling).

Physiological Consequence on Urinary System Structure

This mechanism-driven decrease in localized swelling and physical irritation is the key physiological consequence of the drug's action. The reduction of tissue volume and pressure decreases tissue-mediated mechanical strain on the adjacent urinary tract structures. This physical change is the key physiological consequence that relates the molecular action to the function of the lower urinary system.

The administration of Афала is defined by specific procedural guidelines, intended solely for the adult male population. The medication is delivered via the oral route, with the distinct requirement that the tablet must be held in the mouth until it is completely dissolved, ensuring absorption through the buccal mucosa. It is explicitly instructed that the tablets should be administered separate from mealtimes.

The dosing schedule operates in two distinct frequency phases, both utilizing a fixed dose of two (2) tablets per administration. For standard use or chronic support, the regimen prescribes two administrations per day, typically taken in the morning and the evening. In situations requiring more intensive support, particularly during the first two to three weeks of treatment, the prescribed frequency may be temporarily increased to up to four times per day. This adjusted schedule defines the initial use pattern, transitioning to the maintenance phase.

A typical continuous course of administration is recommended to last for a duration of 16 weeks (approximately four months). Following the completion of this initial period, guidelines indicate that a repeat course of treatment is possible, if necessary, after an interval of one to four months, establishing a pattern of potential intermittent use. This protocol emphasizes the fixed-dose, non-titrated nature of the preparation's use. The labeling confirms that the tablet's scored line is not intended for breaking the tablet into smaller pieces.

Research Evidence / Overview of Studies for Афала

Evidence for Use in Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS)

The most structured research on this preparation focuses on its use in Benign Prostatic Hyperplasia (BPH), where research explored outcomes related to the associated Lower Urinary Tract Symptoms (LUTS), such as frequent urination or nighttime urges. Investigation in this area has relied on multi-center, double-blind, randomized trials. These study designs were used to explore differences in monitored outcomes between the preparation and an inactive placebo, with neither participants nor researchers knowing who received which preparation.

Studies conducted during periods of increased symptom activity examined patient-reported outcomes, specifically using the International Prostate Symptom Score (IPSS). Studies also included assessments of functional changes, such as the maximum rate of urine flow (Qmax) and the amount of urine left in the bladder after voiding. Findings reported measurements observed during the intermediate follow-up period of up to one year for the total IPSS score and functional measures. The key 12-month trial utilized the combined formulation (Afalaza), which contains the active ingredient to PSA plus antibodies to eNOS, rather than the single-component preparation.

---

Research Structure for Chronic Abacterial Prostatitis

The evidence base for this preparation related to chronic abacterial prostatitis (a non-bacterial, long-term inflammation of the prostate) has primarily relied on preclinical (experimental) studies conducted in animal models and earlier-stage clinical studies. Studies monitored outcomes related to inflammatory or irritative states and examined patient-reported outcomes describing perceived discomfort.

---

What Research Gaps and Uncertainties Remain

Research contributes to the broader evidence landscape but also highlights limitations. One key limitation is that comparative evidence against established conventional therapies is not widely available. Research primarily compared the preparation to a placebo, and there is limited published information available directly comparing it against established drug classes for BPH. Additionally, the highly specific study criteria mean that findings primarily describe the patterns observed in the populations that were included (men aged 45 to 60 with moderate symptoms). Data for men with more advanced BPH or older ages remain insufficient in the primary high-level evidence. Finally, certainty remains low for the chronic prostatitis indication, where the evidence quality varies across studies.

Key Studies & References

1. Prostate-Specific Antigen (PSA) Test

Common questions about Афала (FAQ)

Q: What is the difference between Афала and similar supplements or homeopathic treatments?

According to official product information, Афала is classified as a distinctive homeopathic medicinal product. Its core function is described as a Modulator of Prostate-specific Antigen (PSA) activity, which sets its preparation and mechanism apart from conventional pharmacological classes like alpha-blockers. While the classification is clear, official regulatory documents do not provide direct comparisons to other specific supplements or homeopathic products.

Q: Is Афала safe to use for people who have existing liver conditions?

Official regulatory documents for the preparation do not list specific restrictions or limitations regarding its use in patients with hepatic impairment (liver conditions). The primary eligibility restrictions are related to age, sex, hypersensitivity, and specific metabolic conditions. Official regulatory guidance does not contain a specific statement on dose adjustments or cautions related to liver issues.

Q: Is Афала safe for people who have existing kidney problems?

Similar to liver conditions, the official regulatory documents do not list specific limitations or restrictions concerning the use of the preparation in patients with renal impairment (kidney problems). Official eligibility criteria focus on age, sex, hypersensitivity, and specific metabolic conditions.

Q: What is the recommended time of day for taking Афала?

Official administration guidelines indicate the preparation is typically taken in the morning and the evening. The tablets must be taken separate from mealtimes, as emphasized in the official instructions.

Q: Are there official research findings published on the long-term use of Афала?

Research evidence exploring outcomes related to prostate symptoms has relied on multi-center trials with an intermediate follow-up period. Findings reported in official sources generally cover outcomes measured for up to approximately one year. Published information available beyond a one-year follow-up is limited.

Q: Does the effectiveness of Афала depend on the patient's age?

Official research evidence notes that the findings primarily describe the patterns observed in men aged 45 to 60 with moderate symptoms. This indicates that the regulatory data available for men of older ages remains insufficient in the primary high-level evidence.

Q: Does taking Афала require changes to a person's diet or lifestyle?

Official regulatory instructions note the tablet should be administered separate from mealtimes for proper use. Beyond this timing constraint, official labeling contains no documented specific interactions with food, alcohol, or supplements. Furthermore, no mandatory changes to general lifestyle habits are outlined in the official product information.

Q: Is there any evidence to suggest that Афала's effect wears off over time?

Findings from the 12-month clinical trial indicated that the observable effect on symptoms was maintained throughout the observation period. During the trial period, there was no tendency observed for the effect to diminish or 'plateau' over time.

The official labeling dictates precise conditions for storing and disposing of Афала tablets to ensure stability and public safety.

Storage Requirements

The product must be stored at a temperature not exceeding 25 C. It is mandatory to keep the tablets in a dry, dark place and maintain them in the manufacturer's original cardboard carton throughout the entire 3-year shelf life. The medicine must always be stored out of the reach of children.

Disposal Instructions

Any unused or expired Афала tablets must be discarded in accordance with local requirements. Users should refer to established procedures for pharmaceutical waste in their region for proper disposal.